Foreign Drugmakers Now Getting More GMP Warning Letters Than U.S. Firms
This article was originally published in The Pink Sheet Daily
For the first time, this fiscal year FDA seems to be on track to send more warning letters to foreign manufacturers of finished pharmaceuticals and APIs than their domestic counterparts.
You may also be interested in...
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.